Genomes and Genes
anti hiv agents
Summary: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Articles from Journal RESEARCH
Articles from Journal RESEARCH1
Publications342 found, 100 shown here
- Early antiretroviral therapy and mortality among HIV-infected infantsAvy Violari
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
N Engl J Med 359:2233-44. 2008..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyT W Chun
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 94:13193-7. 1997..In addition, the presence of unintegrated HIV-1 DNA in infected resting CD4+ T cells from patients receiving HAART, even those with undetectable plasma viremia, suggests persistent active virus replication in vivo...
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionJason M Brenchley
Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Med 12:1365-71. 2006..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJoel E Gallant
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
JAMA 292:191-201. 2004..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
- Human immunodeficiency virus reverse transcriptase and protease sequence databaseSoo Yon Rhee
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
Nucleic Acids Res 31:298-303. 2003..Sequence data on two new molecular targets of HIV drug therapy--gp41 (cell fusion) and integrase--will be added to the database in 2003...
- Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyJeffrey A Johnson
Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
PLoS Med 5:e158. 2008..We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants...
- Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysisSuzanna Attia
Institute of Social and Preventive Medicine, University of Bern, Switzerland
AIDS 23:1397-404. 2009..To synthesize the evidence on the risk of HIV transmission through unprotected sexual intercourse according to viral load and treatment with combination antiretroviral therapy (ART)...
- Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistanceChunlin Wang
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
Genome Res 17:1195-201. 2007..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
- Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysisEdward J Mills
Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
JAMA 296:679-90. 2006..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
- Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV diseaseB Autran
Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
Science 277:112-6. 1997..Thus, decreasing the HIV load can reverse HIV-driven activation and CD4(+) T cell defects in advanced HIV-infected patients...
- Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationD R Bangsberg
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, University of California San Francisco, 94110, USA
AIDS 14:357-66. 2000..To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy...
- Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppressionDavid R Bangsberg
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, and the Positive Health Program, San Francisco General Hospital, University of California, San Francisco, CA 94143 1372, USA
Clin Infect Dis 43:939-41. 2006..Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens...
- Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapyJean Jacques Parienti
Department of Infectious Diseases and Virology, Côte de Nacre Hospital, Caen, France
Clin Infect Dis 38:1311-6. 2004..8-180.3; P<.0001). Patients' previous adherence to therapy and drugs genetic barriers, not only the number of pills or doses involved, should be taken into consideration in the decision to simplify highly active antiretroviral therapy...
- Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupA Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK
Lancet 352:1725-30. 1998..We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens...
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyJ B Dinoso
Departmentsof Medicine and Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Proc Natl Acad Sci U S A 106:9403-8. 2009..Our results suggest that residual viremia is not the product of ongoing, complete cycles of viral replication, but rather of virus output from stable reservoirs of infection...
- Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomesBirgitte B Simen
454 Life Sciences, a Roche Company, Branford, Connecticut, USA
J Infect Dis 199:693-701. 2009..Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important...
- Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomesJeffrey S A Stringer
Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
JAMA 296:782-93. 2006..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
- Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settingsMathieu Forster
Institute of Social and Preventive Medicine, University of Bern, Switzerland
Bull World Health Organ 86:939-47. 2008....
- Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infectionT W Chun
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 95:8869-73. 1998....
- When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky
Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
Ann Intern Med 151:157-66. 2009..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
- Depletion of latent HIV-1 infection in vivo: a proof-of-concept studyGinger Lehrman
University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
Lancet 366:549-55. 2005..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
- Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmissionNewton I Kumwenda
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
N Engl J Med 359:119-29. 2008..Effective strategies are urgently needed to reduce mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) through breast-feeding in resource-limited settings...
- HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoirTae Wook Chun
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
J Clin Invest 115:3250-5. 2005..Such events may allow continual replenishment of the CD4+ T cell reservoir and resetting of the half-life of the latently infected, resting CD4+ T cells despite prolonged periods of aviremia...
- Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South AfricaDavid Coetzee
Infectious Disease Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory 7925, South Africa
AIDS 18:887-95. 2004....
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth
International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Lancet 363:1253-63. 2004..The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz...
- Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little
Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
N Engl J Med 347:385-94. 2002..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
- HIV-1 protease and reverse transcriptase mutations for drug resistance surveillanceRobert W Shafer
Division of Infectious Diseases, Stanford University, Stanford, California, USA
AIDS 21:215-23. 2007..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...
- Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsUme L Abbas
Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
PLoS ONE 2:e875. 2007..The potential impact of pre-exposure chemoprophylaxis (PrEP) on heterosexual transmission of HIV-1 infection in resource-limited settings is uncertain...
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyMarguerite Guiguet
INSERM U943 and UPMC UMR S 943, Paris, France
Lancet Oncol 10:1152-9. 2009..We examined the effect of these factors on the risk of specific cancers in patients infected with HIV-1...
- HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppressionR T Davey
National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 96:15109-14. 1999..Virologic relapse occurs rapidly in patients who discontinue suppressive drug therapy, even in patients with a markedly diminished pool of resting, latently infected CD4(+) T cells...
- Inflammatory and coagulation biomarkers and mortality in patients with HIV infectionLewis H Kuller
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
PLoS Med 5:e203. 2008..We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis...
- Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapyXiping Wei
Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
Antimicrob Agents Chemother 46:1896-905. 2002..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
- Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapyMoses R Kamya
Department of Medicine, Makerere University, Kampala, Uganda
J Acquir Immune Defic Syndr 46:187-93. 2007..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
- Inhibiting sexual transmission of HIV-1 infectionRobin J Shattock
Department of Cellular and Molecular Medicine, Infectious Diseases, St George s Hospital Medical School, London, UK
Nat Rev Microbiol 1:25-34. 2003....
- Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyPatricia Cane
BMJ 331:1368. 2005..To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom...
- Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Gerd Fatkenheuer
Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
Nat Med 11:1170-2. 2005..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
- Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
JAMA 296:794-805. 2006..Postnatal transmission of human immunodeficiency virus-1 (HIV) via breastfeeding reverses gains achieved by perinatal antiretroviral interventions...
- Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in UgandaSteven J Reynolds
National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
AIDS 23:697-700. 2009..Our objective was to evaluate immunologic failure criteria against gold standard virologic monitoring...
- In vitro and in vivo: the story of nonoxynol 9Sharon L Hillier
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Acquir Immune Defic Syndr 39:1-8. 2005..This article presents a review of the in vitro, ex vivo, and animal model data on the safety of N-9 and a critical analysis of their predictive power based on the results of multiple safety and efficacy trials...
- Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremiaS G Deeks
University of California, San Francisco, and San Francisco General Hospital, USA
N Engl J Med 344:472-80. 2001..In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown...
- The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1E Oberlin
Unite d Immunologie Virale, Institut Pasteur, Paris, France
Nature 382:833-5. 1996....
- Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patientsPatricia Garcia de Olalla
Epidemiology Service, Municipal Institute of Public Health of Barcelona, and Autónoma University of Barcelona, Spain
J Acquir Immune Defic Syndr 30:105-10. 2002..To assess the effect of antiretroviral therapy (ART) adherence on survival in HIV-infected patients...
- Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch
Harvard Medical School, Boston, MA, USA
JAMA 279:1984-91. 1998..To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice...
- Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequencyElias K Halvas
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, and Children s Hospital of Los Angeles, CA, USA
J Clin Microbiol 44:2612-4. 2006..1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy...
- A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitorsBluma Brenner
McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
AIDS 17:F1-5. 2003..This study evaluates the prevalence of V106 (GTG) and 106M (ATG) codons in clinical isolates as well as the effects of V106M on resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI)...
- Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsGraeme Meintjes
Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
Lancet Infect Dis 8:516-23. 2008..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve PatientsA d'Arminio Monforte
Institute of Infectious and Tropical Diseases, University of Milan, Italy
AIDS 14:499-507. 2000....
- Learning multiple evolutionary pathways from cross-sectional dataNiko Beerenwinkel
Max Planck Institut für Informatik, Stuhlsatzenhausweg 85, D 66123 Saarbrucken, Germany
J Comput Biol 12:584-98. 2005..We obtain a generative probabilistic model for the development of drug resistance in HIV that agrees with biological knowledge. Further applications and extensions of the model are discussed...
- Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitorShawn E Kuhmann
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
J Virol 78:2790-807. 2004..2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex...
- CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infectionJason V Baker
University of Minnesota, Minneapolis, USA
AIDS 22:841-8. 2008..Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients...
- Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infectionM S Sulkowski
Department of Medicine, Johns Hopkins University Schools of Medicine, Baltimore, MD 21287, USA
JAMA 283:74-80. 2000..Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus...
- Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'IvoireGaston Djomand
Projet RETRO CI, Abidjan, Cote d Ivoire
AIDS 17:S5-15. 2003..This evaluation of the project is the first to provide results of a large number of HIV-infected patients receiving antiretroviral therapy in West Africa...
- Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26Hiroyuki Gatanaga
AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan
Clin Infect Dis 45:1230-7. 2007..Here, we tested the feasibility of genotype-based dose reduction of EFV...
- Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central ChinaHonghong Wang
School of Nursing, Central South University, Changsha, Hunan, China
AIDS Patient Care STDS 22:71-80. 2008..Prospective studies are needed to evaluate the efficacy of reminder devices to improve adherence in this population and to describe the prevalence and incidence of ARV resistance...
- Prevalence and predictive value of intermittent viremia with combination hiv therapyD V Havlir
University of California, San Diego, 150 W Washington, Suite 100, San Diego, CA 92103, USA
JAMA 286:171-9. 2001....
- HIV drug resistanceFrancois Clavel
Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
N Engl J Med 350:1023-35. 2004
- Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patientsPierre De Beaudrap
Hospices Civils de Lyon, Service de Biostatistique, Lyon, F 69424, France
AIDS Res Hum Retroviruses 24:753-60. 2008..Adverse effects were different between NVP and EFV, but long-term tolerance was good for both. This analysis provided further information on long-term tolerance and efficacy of EFV and NVP in a resource-limited setting...
- Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'IvoireRaoul Moh
Programme PAC CI, Abidjan, Cote d Ivoire
Antivir Ther 10:615-24. 2005..We estimated the incidence of haematological disorders during the first 6 months of a zidovudine-containing highly active antiretroviral therapy (HAART) regimen in sub-Saharan African adults receiving cotrimoxazole...
- Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptaseP L Boyer
ABL Basic Research Program, National Cancer Institute Frederick Cancer Research and Development Center, Frederick, Maryland 21702 1201, USA
J Virol 75:4832-42. 2001..Steric constraints involving the azido group cause the end of an AZT 5'-monophosphate-terminated primer to preferentially reside at the nucleotide binding site, which favors excision...
- A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patientsJianqing J Yu
Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Virology 379:78-86. 2008..When we applied our integration assay to patient PBMCs, we found that the use of HAART is associated with reduced levels of integrated DNA...
- Antiviral inhibition of the HIV-1 capsid proteinChun Tang
Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250 5398, USA
J Mol Biol 327:1013-20. 2003..These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS...
- Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivitySamir Abdurahman
Division of Clinical Microbiology, Karolinska Institutet, F68 Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
Antimicrob Agents Chemother 52:3737-44. 2008..As an antiviral compound, alpha-HGA has an unusually simple structure, a pronounced antiviral specificity, and a novel mechanism of antiviral action. As such, it might prove to be a lead compound for a new class of anti-HIV substances...
- The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South AfricaSydney Rosen
Center for International Health and Development, Boston University, Boston, MA 02118, USA
Trop Med Int Health 13:1005-15. 2008..Estimate the average outpatient cost per patient in care and responding to treatment 1 year after initiation of antiretroviral therapy (ART) under different models of treatment delivery in South Africa...
- The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entryC C Bleul
The Center for Blood Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Nature 382:829-33. 1996....
- Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonistsRama Kondru
Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
Mol Pharmacol 73:789-800. 2008..The fully mapped binding pocket of CCR5 is being used for structure-based design and lead optimization of novel anti-HIV CCR5 inhibitors with improved potency and better resistance profile...
- Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort studyJean Francois Etard
UMR 145 HIV AIDS and Associated Diseases, Research Institute for Development IRD University of Montpellier, 911 Avenue Agropolis, 34394 Montpellier Cedex 1, France
AIDS 20:1181-9. 2006..To evaluate survival and investigate causes of death among HIV-1 infected adults receiving HAART in Senegal...
- The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsJoel E Gallant
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
AIDS 22:2155-63. 2008..We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144 weeks from two clinical trials in antiretroviral-naive HIV-infected patients...
- HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilizationRon Kagan
Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
AIDS Res Hum Retroviruses 20:1-9. 2004..Continued monitoring of ARV resistance prevalence, patterns, and utilization trends in clinical databases provides insight into the evolving relationship between clinical practice and ARV resistance...
- The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophagesS Aquaro
Laboratory of Experimental Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
J Virol 75:4402-6. 2001..LD78beta strongly downregulated CCR5 expression in M/M, thereby explaining its potent antiviral activity...
- Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD studyNina Friis-Møller
DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
AIDS 17:1179-93. 2003..To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies...
- The cost effectiveness of combination antiretroviral therapy for HIV diseaseK A Freedberg
Division of General Internal Medicine and the Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
N Engl J Med 344:824-31. 2001..We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral regimens...
- A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIVRobert Grossberg
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
J Clin Epidemiol 57:1107-10. 2004..The goal of this study was to determine the validity and utility of a pharmacy-based time-to-refill measure of antiretroviral therapy adherence...
- A cell-penetrating helical peptide as a potential HIV-1 inhibitorHongtao Zhang
Laboratory of Molecular Modeling and Drug Design, Lindsley F Kimball Research Institute of the New York Blood Center, 310 E 67th Street, New York, NY 10021, USA
J Mol Biol 378:565-80. 2008..This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein...
- Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, KenyaJ Odhiambo
United States Centers for Disease Control and Prevention, Nairobi, Kenya
Int J Tuberc Lung Dis 12:63-8. 2008..Integrated tuberculosis (TB) and human immunodeficiency virus (HIV) services in a resource-constrained setting...
- HIV preferentially infects HIV-specific CD4+ T cellsDaniel C Douek
Vaccine Research Center, NIAID, NIH, Maryland 20892, USA
Nature 417:95-8. 2002..Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption...
- Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan AfricaCatherine G Sutcliffe
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Lancet Infect Dis 8:477-89. 2008....
- Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapyR S Hogg
Director, AIDS Research Programme, St Paul's Hospital/University of British Columbia, 667-1081 Burrard St, Vancouver, British Columbia V6Z 1Y6, Canada
JAMA 286:2568-77. 2001..In our study, disease progression to death and AIDS or death was clustered among patients starting therapy with CD4 cell counts less than 200/microL...
- Modelling the effect of combination antiretroviral treatments on HIV incidenceM G Law
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW 2010, Australia
AIDS 15:1287-94. 2001....
- Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimatedJeffrey A Johnson
Laboratory Branch, National Center for HIV, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
J Infect Dis 192:16-23. 2005..These findings indicate that resistance mutations emerged in at least 65% of the women after SD-NVP and emphasize the importance of further research to determine the clinical implications...
- Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trialS Staszewski
Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Infektionsambulanz, Haus 68, Theodor Stern Kai 7, D 60596 Frankfurt, Germany
JAMA 285:1155-63. 2001..However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment...
- Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency programRob Schuurman
Department of Virology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
AIDS Res Hum Retroviruses 18:243-8. 2002..Drug resistance mutations are frequently missed. Therefore, quality control programs are urgently needed. Until these are widely implemented, clinicians must consider this issue and interpret the reported genotyping results with caution...
- Adherence to antiretroviral medication among HIV-positive patients in ThailandWantana Limkulpong Maneesriwongul
Community Health Nursing Division, Nursing Department, Ramathibodi Faculty of Medicine, Mahidol University, Bangkok, Thailand
J Acquir Immune Defic Syndr 43:S119-22. 2006..The use of antiretroviral (ARV) medications is expanding rapidly in Thailand. The determinants of optimal adherence for HIV-positive patients in Thailand are unknown...
- Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypesCatherine Tamalet
Laboratoire de Virologie, CHRU La Timone, 13005 Marseille, France
AIDS 17:2383-8. 2003..The aim of this study was to assess the extent of multiple drug resistance among individuals followed for HIV-1 infection in France...
- Adherence to medication regimens among children with human immunodeficiency virus infectionC Reddington
Pediatric Spectrum of Disease Project, University of Massachusetts Medical School, Jamaica Plain, USA
Pediatr Infect Dis J 19:1148-53. 2000..Rigorous adherence to antiretroviral medication regimens is necessary to achieve and maintain undetectable viral levels. This study describes adherence in a population of children with HIV infection...
- Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapyGregory P Bisson
Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
PLoS Med 5:e109. 2008....
- Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmissionCarey Farquhar
Department of Medicine, University of Washington, Seattle, WA 98104 249, USA
J Acquir Immune Defic Syndr 37:1620-6. 2004..004). Partner participation in VCT and couple counseling increased uptake of nevirapine and formula feeding. Antenatal couple counseling may be a useful strategy to promote HIV-1 prevention interventions...
- In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trialsDeborah Tien
Biosyn, Inc, Huntingdon Valley, PA 19006, USA
AIDS Res Hum Retroviruses 21:845-53. 2005....
- A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibodyS Jiang
The Lindsley F Kimball Research Institute, New York Blood Center, NY 10021, USA
J Virol Methods 80:85-96. 1999....
- Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1A K Debnath
Lindsley F Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, New York 10021, USA
J Med Chem 42:3203-9. 1999..These two compounds will be used as leads to design more effective HIV-1 inhibitors targeted to the HIV-1 gp41 core structure...
- Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysisSarah Palmer
HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Clin Microbiol 43:406-13. 2005..In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis...
- Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patientsMichael D Miller
Gilead Sciences, Foster City, California 94404, USA
J Infect Dis 189:837-46. 2004..The results from these controlled clinical trials provide guidance for the use of tenofovir DF for treatment-experienced patients...
- High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in RwandaJohan van Griensven
Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
Trans R Soc Trop Med Hyg 101:793-8. 2007..Lipoatrophy appears to be an important long-term complication of WHO-recommended first-line ART regimens. These data highlight the urgent need for access to more affordable and less toxic ART regimens in resource-limited settings...
- Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimensK J Roberts
University of California, Los Angeles, USA
AIDS Patient Care STDS 14:155-68. 2000..Other barriers, however, such as the complexity of the medications, highlight the need for simplified antiretroviral regimens...
- Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experienceFreddy Perez
Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Universite Victor Segalen, Bordeaux, France
Trop Med Int Health 9:774-83. 2004..To report on activities and lessons learned during the first 18 months of a rural programme of prevention of mother-to-child transmission of HIV (PMTCT) in Zimbabwe...
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari
Quest Clinical Research, Mount Zion Hospital and the University of California, San Francisco, San Francisco 94115, USA
N Engl J Med 348:2175-85. 2003..The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor...
- Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohortJohn L Perez
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Clin Infect Dis 36:212-8. 2003..28 (95% CI, 0.15-0.52) for treated older adults. The effect of HAART substantially improves the survival rate for older individuals and supports the importance of treatment in this group...
- Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsJiehua Zhou
Division of Molecular Biology, Beckman Research Institute of City of Hope, City of Hope, Duarte, CA 91010, USA
Nucleic Acids Res 37:3094-109. 2009..Our results provide a set of novel inhibitory agents for blocking HIV replication and further validate the use of aptamers for delivery of Dicer substrate siRNAs...
- Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIVErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
Int J Antimicrob Agents 33:307-20. 2009..These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development...
- In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNAMark Sharkey
Program in Molecular Medicine, University of Massachusetts, 373 Plantation St, Biotech 2, Suite 319, Worcester, MA 01605, USA
J Virol 79:5203-10. 2005..Therefore, evolution of episomal viral cDNAs is a valid surrogate of ongoing viral replication in HIV-1-infected individuals...
- Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysisAndrea L Ciaranello
The Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Infect Dis 49:1915-27. 2009..We sought to derive pooled estimates of the 12-month rate of virologic suppression (HIV RNA, <400 copies/mL) and gain in CD4 cell percentage (DeltaCD4%) for children initiating ART in resource-limited settings...
- In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudineRoger Paredes
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Virol 83:2038-43. 2009..After a lag phase of variable duration, wild-type variants emerged due to continued evolution of pol and back mutation rather than through emergence of an archived wild-type variant...
- The Role of Alcohol in HIV Therapy HepatotoxicityCraig J McClain; Fiscal Year: 2012..Here, we will study hepatotoxicity due to alcohol/HAART interactions to further define disease mechanisms and create therapeutic interventions. ..
- Markers of HIV Brain Disease under HAART: Validation in a Mouse ModelDavid J Volsky; Fiscal Year: 2012....
- Effect of Iron Chelators on HIV-1 transcriptionZUFAN KEREGO DEBEBE; Fiscal Year: 2011..These findings will provide information in the search for alternative therapeutic approaches that are hopefully more effective and efficient to treat HIV-1. Iron chelators could add to improve the treatment of HIV disease. ..
- NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTSJURGEN T ROHR; Fiscal Year: 2013..New resulting MTM analogues will be submitted to the NCI DTP (developmental therapeutics program) for further mechanistic investigations. ..
- Enhancing Intestinal &Brain Uptake of Anti-AIDS DrugsPatrick J Sinko; Fiscal Year: 2013....
- Phosphorylation of CDK9 by CDK2 in HIV-1 replicationDenitra Breuer; Fiscal Year: 2011..Our findings from this research will provide valuable information regarding the use of CDK2 as a possible target for HIV-1 drug therapy. ..
- Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) AntagonistsSTEVEN DANIEL DOUGLAS; Fiscal Year: 2013..This NK1RA has activity as an antiviral HIV agent that improves innate immunity (Natural Killer cells) and has positive neurobehavioral effects. NK1RA are a potential novel therapy for neuroAIDS...
- Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101James O Kahn; Fiscal Year: 2010..Specifically the project will examine the medication adherence for antiretroviral medications and common medical and mental health conditions such as depression, hypertension, diabetes and hypercholesterolemia. ..
- SYNTHESIS AND BIOTRANSFORMATION OF ANTI-HIV PRODRUGSChung K Chu; Fiscal Year: 2010..If any prodrugs are found to be promising during these studies, we plan to advance them as clinical candidates. ..
- Rescuing the anti-HIV activity of APOBEC3G with small-molecule chaperonsSergey N Savinov; Fiscal Year: 2010..We propose to develop a novel anti-HIV therapeutic strategy that will rescue the natural antiviral mechanism without the danger of producing drug-resistant viruses. ..
- Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenAWEWURA JACOB KWARA; Fiscal Year: 2013..Without such data, rational decisions about prescribing anti-TB and anti-HIV medications in children are not possible. PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..
- A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS InfectionAlfredo Garzino-Demo; Fiscal Year: 2013..These studies are highly relevant to prevention and treatment of HIV infection because they will contribute knowledge that can be used to develop novel anti-HIV drugs that will target CCR6. ..
- Alternative Formulations of Tenofovir and UC781Lisa C Rohan; Fiscal Year: 2013..Formulation strategies to address solubility and stability issues related with UC781 and alternate film manufacturing techniques will be studied. ..
- Novel targets for discovering peptide inhibitors of HIV-1 replicationXinhong Dong; Fiscal Year: 2011..Our studies will take important steps toward developing the prototype of a novel class of anti-HIV inhibitors. ..
- Discovery of Novel HIV-1 Reverse Transcriptase Inhibitors by Fragment ScreeningANGELA MCKOY; Fiscal Year: 2013..The fragment screening approach allows for efficient search of chemical space and should lead to the identification of novel scaffolds for inhibiting HIV-1 RNH activity at both the active site and allosteric pockets. ..
- Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV AgentsJohn K Buolamwini; Fiscal Year: 2010..The PI has discovered potent integrase inhibitors. The objectives of the grant proposal are to optimize activity and test toxicity. ..
- Cellular Efflux and Metabolism of Protease InhibitorsAshim Mitra; Fiscal Year: 2004..The brain parenchymal and alveolar lining - two sanctuary sites that are 'protected' from optimal antiretroviral drug access. 4) to study the effect of protein binding on the influx and efflux of model compounds, and anti-HIV drugs. ..
- Structure activity and structure property relationships for novel anti-HIV agentsKATHLEEN MARY FREY; Fiscal Year: 2013..The combination of both SAR and SPR for leading NNRTI compounds will prioritize future development and provide structural information for rational drug design of efficacious NNRTIs. ..
- Targeting HIV Capsid AssemblySusana T Valente; Fiscal Year: 2013..Our goal is to provide the scientific community with freely accessible robust assays and potent, diversely acting HIV capsid inhibitors active in nanomolar concentrations. ..
- Modified Triterpines as Potent HIV Fusion InhibitorsKuo Hsiung Lee; Fiscal Year: 2012..The aim is to discover an optimal compound that, with the help of a pharmaceutical partner, can be developed as an anti- AIDS clinical trial candidate and, ultimately, as a new drug to treat AIDS-infected patients. ..
- Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus releasePaula M Cannon; Fiscal Year: 2010..PHS 398 (Rev. 09/04) Page 2 Principal Investigator/Program Director (Last, first, middle): CANNON, PAULA, M ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2010..Therefore, this research is relevant to public health. ..
- DNA SYNTHESIS AND RECOMBINATION BY HIV DNA POLYMERASERobert A Bambara; Fiscal Year: 2011..This mechanism can produce viruses with increased or multi-drug resistance. Our results will help us to understand and defeat this mechanism so that anti-AIDS drugs can be more effective. ..
- Nucleoside Transporters In HAART Mitochondrial ToxicityJohn Buolamwini; Fiscal Year: 2006..abstract_text> ..
- The role of envelope phosphatidylserine in the binding of HIV to target cellsKOKI MORIZONO; Fiscal Year: 2012..Identification of this novel binding mechanism will lead to new approaches to prevent HIV transmission among people and to inhibit HIV replication in patients. ..
- A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancyTHOMAS MICHAEL ZYDOWSKY; Fiscal Year: 2013....
- STRUCTURES AND INTERACTIONS OF CHEMOKINE RECEPTORSZiwei Huang; Fiscal Year: 2010....
- High-throughput screening for HIV assembly and maturation inhibitorsWuyuan Lu; Fiscal Year: 2013..Our long-term objective is to develop HIV assembly and maturation inhibitors as a novel class of therapeutic agents for the prevention of HIV-1 infection and the treatment of AIDS. ..
- Determinates of anti-HIV nucleic acid aptamer potency and resistanceDonald H Burke; Fiscal Year: 2012....
- CNS targeted delivery of anti-HIV drugsRodney J Y Ho; Fiscal Year: 2010..We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood. ..
- The Biosynthesis of Ladderane LipidsReid McCarty; Fiscal Year: 2013....
- POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIVKarl Y Hostetler; Fiscal Year: 2010..This proposal is to evaluate and develop one of five highly potent new antiviral phosphonates of our design for treatment of drug resistant HIV infection. ..
- Expanded Phase II Trial of Carraguard for Prevention of HPV InfectionMark H Einstein; Fiscal Year: 2013..Decreasing HPV rates would have a significant impact on reducing persistent HPV infection, abnormal Pap tests, and cervical cancer nationally and worldwide. ..
- Bioactivity of Aptamers Targeted to HIV Reverse TranscriptaseMargaret J Lange; Fiscal Year: 2012..In addition to the potential for therapeutic application, the project will increase understanding of HIV resistance. ..
- ANTI-AIDS NUCLEOSIDE CONJUGATES OF ETHER PHOSPHOLIPIDSCHUNG HONG; Fiscal Year: 1992..The proposed conjugates and the micelle-solubilized drug formulation will be sent to the National Institute of Allergy and Infectious Diseases for screening of anti-HIV activity...
- Development of Novel Nucleoside Triphosphate ProdrugsBYRON WILLIS PURSE; Fiscal Year: 2012..The results of these studies will be used to direct the synthesis of prodrugs of 3'- azido-3'-deoxythymidine triphosphate that will be tested as inhibitors of HIV. ..
- pH Responsive anti-HIV NanoparticlesRodney J Y Ho; Fiscal Year: 2013..The proposed novel strategies are designed to address this unmet medical need and may eventually lead to a cure for HIV/AIDS. ..
- EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMSERIN ALLEN; Fiscal Year: 2013..Alternatively, non-hormonal contraceptive drugs may provide an opportunity to be able to be combined with anti-HIV drugs and provide dual purpose protection. ..
- Synthesis of Novel Water-Soluble Glycodendrimers as Anti-HIV AgentsKATHERINE MCREYNOLDS; Fiscal Year: 2009..This research seeks to develop a new class of anti-HIV drugs. ..
- HIV-1 reverse transcriptase structure: function, inhibition, and resistanceEDWARD V ARNOLD; Fiscal Year: 2013..The proposed studies will enhance opportunities for targeting known and new sites on RT including RNase H, the only HIV enzyme not yet blocked by anti-AIDS drugs. ..
- Computer-Aided Design of Anti-HIV DrugsWilliam L Jorgensen; Fiscal Year: 2013..Similar analyses are being carried out for the other prominent clinical variant, Lys103Asn;only a ca. 10-fold gain is needed to bring the potency towards strains with this replacement to the 10-nM level. ..
- Targeting HIV infectivity by stimulating cholesterol effluxMICHAEL ILYA BUKRINSKY; Fiscal Year: 2010..These agents target HIV infectivity by a mechanism different from that of other anti-HIV drugs, and thus would be a useful addition to a drug combination used for highly active anti-retroviral therapy. ..
- Betulinic acid derivatives as anti-HIV agentsChin Ho Chen; Fiscal Year: 2013..The proposed study is expected to overcome this drug resistance and, as a result, will have high impact on developing anti-HIV-1 maturation inhibitors for AIDS therapy. ..
- CENTRAL NERVOUS SYSTEM STRATEGIES TARGETING THE HIV SANCBradley Anderson; Fiscal Year: 2003..As observed in children, the infant macaques exhibit a higher incidence of neuro-AIDS than adults which can be characterized by delays in neurological development. ..
- Efficacy Testing of HIV-Specific Microbicides in Humanized MiceRamesh Akkina; Fiscal Year: 2012..4. Evaluate a combinatorial microbicide strategy using select anti-HIV agents with different modes of action. 5. Evaluate the safety and potential toxicities of promising microbicide candidates in vivo. ..
- NEW PHENYL NUCLEOSIDES AS ANTI-HIV AGENTSShashikant Phadtare; Fiscal Year: 2003..abstract_text> ..
- BOTANICAL/DRUG INTERACTIONS IN HIV: GLUCURONIDATIONPhilip Smith; Fiscal Year: 2004..Piperine will also be examined in vitro for potential inhibition of oxidative metabolism of anti-HIV drugs such as the protease inhibitors. ..
- High-throughput Computational Docking Screen for Small-molecule Inhibitors of HIVSimon Cocklin; Fiscal Year: 2011..The compounds identified within this proposal have the potential to serve as templates for novel anti-HIV agents while also providing reagents with which to dissect the basic biology of HIV-1. ..
- Discovery of drugs for use in the treatment and prevention of HIV infection usingDUANE contact RUFFNER; Fiscal Year: 2011..PUBLIC HEALTH RELEVANCE: We will use innovative new technology to develop optimized anti-HIV agents with a variety of mechanisms. These agents will be leads for clinical development. ..
- Interaction between HIV-1 Vif and a Host Key Immune Regulator ComponentSEAN LAMONTE EVANS; Fiscal Year: 2012..Understanding the interactions between these two molecules will help improve the strategy for finding inhibitors that can block this interaction, thus providing a potential for novel anti-HIV drugs. ..
- Inhibitors Targeting HIV Integrase MultimersJacques J Kessl; Fiscal Year: 2012..Aim 1 will focus to increase the binding specificity and affinity of compound 1 for the "bottom" pocket;aim 2 will rationally design new allosteric molecules selectively binding the "side" pocket. ..
- Peptide Inhibitors of HIV-1 Vif FunctionJohn Donahue; Fiscal Year: 2007..This research is relevant to public health because it may lead to the development of new therapeutic agents for the treatment of HIV/AIDS. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
- Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV AgentsJohn Buolamwini; Fiscal Year: 2009..The results of the research will determine whether to carry on with further work on optimizing this class of new anti-HIV agents towards AIDS therapeutics development. ..
- Synthesis of New NNRTLs for the Treatment of AIDSMark Cushman; Fiscal Year: 2005..The activities of the ADAMs vs. NNRTI resistant viruses will be investigated. The aqueous solubilities of the new ADAMs will be measured accurately. ..
- SYNTHESIS ANTI-HIV AGENTS THAT TARGET ZINC FINGERSMARK WELKER; Fiscal Year: 2000..Isolable thiolate conjugates would also be subjected to the battery for screens described in Specific Aim 1. ..
- PLANT ANTI-HIV AGENTSKuo Hsiung Lee; Fiscal Year: 2013..abstract_text> ..
- NOVEL APPROACHES TO THE DISCOVERY OF ANTI-HIV AGENTSYitzhak Tor; Fiscal Year: 2007..Potent and specific effectors of essential regulatory events will significantly advance the development of highly active antiretroviral agents. ..
- FLP-102: Rationally Engineered Antiviral ProteinOSMOND D CRUZ; Fiscal Year: 2003..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
- MECHANISMS OF SELECTIVE ACTIONS OF ANTIVIRAL AGENTSRam Agarwal; Fiscal Year: 2003..HIV sensitivity to 3TC, ddC, and AZT in the resistant cells will be examined by p24 analysis. Understanding of these factors will help design strategies to improve effectiveness of the antiviral agents. ..
- ORAL BIOAVAILABILITY AND VARIABILITY OF ANTIAIDS DRUGSPatrick Sinko; Fiscal Year: 2000....
- Intravaginal ring microbicide formulations comprising multiple anti-HIV agentsThomas Smith; Fiscal Year: 2009..We propose to utilize this platform technology to develop long-term vaginal ring formulations for the potential microbicides tenofovir and TMC-120. ..
- Statistical Methods for Complex HIV Cohort StudiesPeter Bacchetti; Fiscal Year: 2004..Applications to relevant data sets will provide both realistic testing and new substantive insights. Software implementing the methods and technical papers will be available through the Internet at a project-related website. ..
- Synthesis/Biological evaluation of Anti-HIV NucleosidesDavid Chu; Fiscal Year: 2005..This is the first such studies demonstrating the potential of this molecular modeling approach. ..
- Chemokine receptor CCR5 antagonists as novel anti-HIV agentsYan Zhang; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..